Back to search results

Observational Study on Minimally Invasive Surgery for Intracerebral Hemorrhage

This is an observational study looking at how well minimally invasive surgery (MIS) works for people who have had a spontaneous intracerebral hemorrhage (ICH), which is a type of stroke caused by bleeding in the brain. Researchers want to see the real-world effects of this surgery. You might be able to join if you are 18 or older, have had a head CT scan showing an acute, spontaneous ICH with a certain amount of bleeding (at least 20 mLs), and had minimally invasive surgery within 7 days of the bleeding. The study will measure success by looking at your recovery 180 days after the bleeding and how many people pass away within 30 days. The current status of this study is unclear, and it aims to include 2500 participants.

Study design
This is an observational study, meaning researchers will watch and collect information without giving specific treatments. It aims to enroll 2500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants' recovery will be assessed 180 days after the hemorrhage, and mortality will be tracked for 30 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07651631

Rapid Evacuation and Access of Cerebral Hemorrhage Registry

Recruiting
Not specifiedAges 18+Observational
Emory University
~2,500 participants
Updated 2026-08-26 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Modified Rankin Scale (mRS) at 180 Days
Measured over Day 180 from baseline (±14 days)
+1 more outcome measured

Conditions

Intracerebral Hemorrhage

Explore related trials

Cerebral Hemorrhage

Where it's being run

1 sites across 1 states
Georgia1

Study leadership

  • Alex Hall, DHSc · PRINCIPAL_INVESTIGATOR · Emory University
  • Gustavo Pradilla, MD · PRINCIPAL_INVESTIGATOR · Emory University
  • Jonathan Ratcliff,, MD, MPH · PRINCIPAL_INVESTIGATOR · Emory University

Who to contact

Alex Hall, DHSc
[email protected]
404-778-1585
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Head CT demonstrating an acute, spontaneous, intracerebral hemorrhage
Hemorrhage volume ≥ 20 mLs
Minimally invasive surgical intervention performed within 7 days of hemorrhage

Exclusion

Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, recurrence of a recent ICH (\<1 year), as diagnosed with radiographic imaging
Infratentorial intraparenchymal hemorrhage, including midbrain, pontine, or cerebellum
Initial hospital arrival ≥ 24 hours after the onset of stroke symptoms
Last known normal is unknown
Historical Modified Rankin Score \> 4
Known life-expectancy of less than 1 year prior to ICH
DNR or comfort measures only
Known pregnancy in female subjects
Inability or unwillingness of subject or legal guardian/representative to give written informed consent within 7 days of initial hospital arrival
Inability to meet follow up requiremen

What this trial measures

  • Modified Rankin Scale (mRS) at 180 DaysDay 180 from baseline (±14 days)

    Functional outcome will be assessed using the modified Rankin Scale (mRS), a 7-level ordinal scale ranging from 0 (no symptoms) to 6 (death). The primary endpoint evaluates real-world functional recovery following minimally invasive surgery (MIS) for acute supratentorial ICH. Structured interview performed in person or via telephone by trained study personnel; audio-recorded and centrally adjudicated.

  • 30-Day MortalityDay 30 (±7 days)

    All-cause mortality within 30 days of the initial hemorrhage.